Auris Medical

$3.09
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.19 (-5.86%) Today
+$0.04 (+1.31%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell Auris Medical and other stocks, options, and ETFs commission-free!

About EARS

Auris Medical Holding Ltd. engages in the development of novel products that address unmet medical needs in neurotology and central nervous system disorders. The firm focuses on the development of intranasal betahistine for the treatment of vertigo and for the prevention of antipsychotic-induced weight gain and somnolence. It also includes other programs under development such as Keyzilen, for the treatment of acute inner ear tinnitus; and Sonsuvi, for the treatment of acute inner ear hearing loss. The company was founded by Thomas Meyer in 2003 and is headquartered in Hamilton, Bermuda. The listed name for EARS is Auris Medical Holding Ltd. Common Shares 0.01 SF (Bermuda).

CEO
Thomas Meyer
Employees
12
Headquarters
Hamilton, Hamilton
Founded
2003
Market Cap
35.68M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
1.11M
High Today
$3.40
Low Today
$2.92
Open Price
$3.12
Volume
637.66K
52 Week High
$6.60
52 Week Low
$0.65

EARS Earnings

Q4 FY18
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Estimated
— per share
Actual
Available Mar 31, Pre-Market

You May Also Like

BAL
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure